Combination drug treatment in hypertension

Pharmacological Research

Volumn 125, Issue , 2017, Pages 266-271

  Tsioufis, Costas ^a   Thomopoulos, Costas ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HELENA VENIZELOU HOSPITAL   (Greece)

Author keywords

Clinical trials; Combination treatment; Fixed dose combination; Renin angiotensin system blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SYSTOLIC BLOOD PRESSURE; COMBINATION DRUG THERAPY; DRUG COMBINATION;

ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION;

EID: 85029691440     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.09.011     Document Type: Review

References (49)

1. Ezzati, M., Riboli, E., Behavioral and dietary risk factors for noncommunicable diseases. N. Engl. J. Med. 369 (2013), 954–964.
2. Chow, C.K., Teo, K.K., Rangarajan, S., Islam, S., Gupta, R., Avezum, A., et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310 (2013), 959–968.
3. Redon, J., Mourad, J.J., Schmieder, R.E., Volpe, M., Weiss, T.W., Why in 2016 are patients with hypertension not 100% controlled? A call to action. J. Hypertens. 34 (2016), 1480–1488.
4. Isles, C.G., Walker, L.M., Beevers, G.D., Brown, I., Cameron, H.L., Clarke, J., et al. Mortality in patients of the glasgow blood pressure clinic. J. Hypertens. 4 (1986), 141–156.
5. Benetos, A., Thomas, F., Bean, K.E., Guize, L., Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J. Hypertens. 21 (2003), 1635–1640.
6. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels–updated overview and meta-analyses of randomized trials. J. Hypertens. 34 (2016), 613–622.
7. Mancia, G., Rea, F., Cuspidi, C., Grassi, G., Corrao, G., Blood pressure control in hypertension: pros and cons of available treatment strategies. J. Hypertens. 35 (2017), 225–233.
8. Wolff, F.W., Lindeman, R.D., Effects of treatment in hypertension: results of a controlled study. J. Chronic. Dis. 19 (1966), 227–240.
9. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 202 (1967), 1028–1034.
10. Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., et al. ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J. Hypertens. 2013:31 (2013), 1281–1357.
11. Thoenes, M., Neuberger, H.R., Volpe, M., Khan, B.V., Kirch, W., Böhm, M., Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J. Hum. Hypertens. 24 (2010), 336–344.
12. ADVAN.E Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 37 (2007), 829–840.
13. PROGRESS Collaborative Group. Randomised trial of a perindopril based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (2001), 1033–1041.
14. Jamerson, K., Weber, M.A., Bakris, G.L., Dahlof, B., Pitt, B., Shi, V., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359 (2008), 2417–2428.
15. Liu, L., Zhang, Y., Liu, G., Li, W., Zhang, X., Zanchetti, A., The Felodipine event reduction (FEVER) study: a randomized long-term placebo controlled trial in Chinese hypertensive patients. J. Hypertens. 23 (2005), 2157–2172.
16. Julius, S., Kjeldsen, S.E., Weber, M., Brunner, H.R., Ekman, S., Hansson, L., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004), 2022–2031.
17. Black, H.R., Elliott, W.J., Grandits, G., Grambsch, P., Lucente, T., White, W.B., et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 289 (2003), 2073–2082.
18. Zanchetti, A., Bond, M.G., Hennig, M., Neiss, A., Mancia, G., Dal Palu‘, C., et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106 (2002), 2422–2427.
19. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358 (2008), 1547–1559.
20. Fried, L.F., Emanuele, N., Zhang, J.H., Brophy, M., Conner, T.A., Duckworth, W., et al. combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 369 (2013), 1892–1903.
21. Parving, H.H., Brenner, B.M., McMurray, J.J., de Zeeuw, D., Haffner, S.M., Solomon, S.D., et al. cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367 (2012), 2204–2213.
22. Coope, J., Warrender, T.S., Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 293 (1986), 1145–1151.
23. Dahlof, B., Lindholm, L.H., Hansson, L., Schersten, B., Ekbom, T., Wester, P.O., Morbidity and mortality in the swedish trial in old patients with hypertension (STOP-hypertension). Lancet 338 (1991), 1281–1285.
24. Hansson, L., Lindholm, L.H., Ekbom, T., Dahlof, B., Lanke, J., Schersten, B., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with hypertension-2 study. Lancet 354 (1999), 1751–1756.
25. SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension final results of the systolic hypertension in the elderly program (SHEP). JAMA 265 (1991), 3255–3264.
26. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G., de Faire, U., et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002), 995–1003.
27. Elliott, W.J., Meyer, P.M., Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369 (2007), 201–207.
28. Wald, D.S., Law, M., Morris, J.K., Bestwick, J.P., Wald, N.J., Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122 (2009), 290–300.
29. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J. Hypertens. 34 (2016), 1921–1932.
30. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs–overview and meta-analyses. J. Hypertens. 33 (2015), 195–211.
31. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs–overview and meta-analyses. J. Hypertens. 33 (2015), 1321–1341.
32. Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur. Heart. J. 2016:37 (2016), 2129–2200.
33. Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., et al. ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology. Eur. Heart J. 34 (2013), 2949–3003.
34. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events—meta-analyses of randomized trials. J. Hypertens. 34 (2016), 1451–1463.
35. Alderman, M.H., Cohen, H.W., Sealey, J.E., Laragh, J.H., Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am. J. Hypertens. 17 (2004), 1–7.
36. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288 (2002), 2981–2997.
37. Zhang, Y., Zhang, X., Liu, L., Zanchetti, A., Is a systolic blood pressure target <140 mm Hg indicated in all hypertensives: subgroup analyses of findings from the randomized FEVER trial. Eur. Heart J. 32 (2011), 1500–1508.
38. Dahlof, B., Sever, P.S., Poulter, N.R., Wedel, H., Beevers, D.G., Caulfield, M., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005), 895–906.
39. Doumas, M., Douma, S., The effect of antihypertensive drugs on erectile function: a proposed management algorithm. J. Clin. Hypertens. (Greenwich) 8 (2006), 359–364.
40. Law, M.R., Morris, J.K., Wald, N.J., Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.
41. Kario, K., Proposal of RAS-diuretic vs.: RAS-calcium antagonist strategies in high-risk hypertension: insight from the 24-hour ambulatory blood pressure profile and central pressure. J. Am. Soc. Hypertens. 4 (2010), 215–218.
42. Thomopoulos, C., Skalis, G., Makris, T., Resistant hypertension: a real entity or a phantom diagnosis. J. Clin. Hypertens. (Greenwich) 17 (2015), 578–579.
43. Williams, B., MacDonald, T.M., Morant, S., Webb, D.J., Sever, P., McInnes, G., et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386 (2015), 2059–2068.
44. Mahfoud, F., Schmieder, R.E., Azizi, M., Pathak, A., Sievert, H., Tsioufis, C., et al. Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur. Heart J., 2017, 10.1093/eurheartj/ehx215.
45. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels–overview and meta-analyses of randomized trials. J. Hypertens. 32 (2014), 2296–2304.
46. Yusuf, S., Lonn, E., Pais, P., Bosch, J., López-Jaramillo, P., Zhu, J., et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N. Engl. J. Med. 374 (2016), 2032–2043.
47. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk-overview and meta-analyses of randomized trials. J. Hypertens. 32 (2014), 2305–2314.
48. Laurent, S., Parati, G., Chazova, I., Sirenko, Y., Erglis, A., Laucevicius, A., Farsang, C., Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension. J. Hypertens. 33 (2015), 653–661.
49. Mancia, G., Asmar, R., Amodeo, C., Mourad, J.J., Taddei, S., Gamba, M.A., et al. Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. J. Hypertens. 33 (2015), 401–411.